Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
IPO Year: 2019
Exchange: NASDAQ
Website: kaleido.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/31/2022 | $11.00 → $3.00 | Buy | Chardan Capital |
| 11/12/2021 | $15.00 → $11.00 | Buy | Chardan Capital |
| 11/3/2021 | $25.00 → $22.00 | Market Outperform | JMP Securities |
| 10/19/2021 | $3.00 | Equal-Weight → Underweight | Morgan Stanley |
For Immediate Release: September 07, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: As part of the FDA’s effort to protect consumers, the agency issued a warning letter to Kaleido Biosciences, Inc. for not complying with federal laws and regulations, including laws and regulations to protect individuals participatin
4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)
4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)
4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)
4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)
4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)
4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)
4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)
4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)
3 - Kaleido Biosciences, Inc. (0001751299) (Issuer)
4 - Kaleido Biosciences, Inc. (0001751299) (Issuer)
SC 13G/A - Kaleido Biosciences, Inc. (0001751299) (Subject)
SC 13G/A - Kaleido Biosciences, Inc. (0001751299) (Subject)
SC 13G - Kaleido Biosciences, Inc. (0001751299) (Subject)
SC 13D/A - Kaleido Biosciences, Inc. (0001751299) (Subject)
15-12B - Kaleido Biosciences, Inc. (0001751299) (Filer)
EFFECT - Kaleido Biosciences, Inc. (0001751299) (Filer)
S-8 POS - Kaleido Biosciences, Inc. (0001751299) (Filer)
S-8 POS - Kaleido Biosciences, Inc. (0001751299) (Filer)
S-8 POS - Kaleido Biosciences, Inc. (0001751299) (Filer)
POS AM - Kaleido Biosciences, Inc. (0001751299) (Filer)
25 - Kaleido Biosciences, Inc. (0001751299) (Filer)
8-K - Kaleido Biosciences, Inc. (0001751299) (Filer)
NT 10-K - Kaleido Biosciences, Inc. (0001751299) (Filer)
8-K - Kaleido Biosciences, Inc. (0001751299) (Filer)
BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ:RDUS), today announced appointments to new roles on its executive leadership team, effective immediately. Mark Conley has joined Radius as the Company's Chief Financial Officer. In addition, Kim Clarke has been promoted to the General Counsel position. Both will report to Kelly Martin, the Chief Executive Officer. Mark Conley is a Certified Public Accountant with over 30 years of experience in publicly listed companies. His experience includes all aspects of finance including business unit accounting, regulatory, corporate books and records, budget processes, internal & external audit a
CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for
CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h
Company increases industry expertise with the appointments of Laurens Kruidenier, Ph.D., as Chief Scientific Officer; Anna O'Driscoll as Chief People Officer, and Parul Doshi as Senior Vice President, Head of Data and Software Engineering Cellarity, a life sciences company founded by Flagship Pioneering to encode and simulate human biology to reimagine the way we create medicines, announced today the expansion of its executive leadership team with three key appointments. As Chief Scientific Officer, Laurens Kruidenier, Ph.D., will lead the continued evolution of Cellarity's platform and pipeline and oversee cross functional integration across all aspects of computation, drug creation, and
CAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President and Head of Platform Biology. Dr. Milstein most recently served as the Vice President of platform biology at Korro Bio, Inc., and previously led the RNAi Lead Development group at Alnylam Pharmaceuticals, Inc. Dr. Milstein will be responsible for advancing Senda's platform and scaling the Company's efforts to unlock a new class of fully programmable medicines.
CAMBRIDGE, Mass., Jan. 25, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Tom DiLenge has joined the company in a newly created role as Senior Partner, Global Public Policy, Regulatory & Governmental Strategy. In this role, DiLenge will lead and develop Flagship's public policy, regulatory, and government affairs functions to advance Flagship's priorities at the federal, state, and global levels. In addition, he will serve as an in-house advisor and expert resource to Flagship's ecosystem companies. Tom brings to Flagship Pi
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that the topline data obtained with KB295, a novel Microbiome Metabolic Therapy (MMT™), in mild-to-moderate ulcerative colitis (UC), will be presented virtually at the 2022 Crohn's and Colitis Congress. "The data show the direct effect of administering KB295 includes enriching diverse, beneficial commensal microbiota and restoring balanced SCFA production, while depletin
Estepan brings to Cellarity's BOD deep experience and expertise in all aspects of finance, corporate strategy, investor relations, and business development, and a dedication to directly improving patient lives through innovation in medicine Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointment of Ian M. Estepan to its Board of Directors. Mr. Estepan currently serves as Executive Vice President and Chief Financial Officer (CFO) of Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases. At Sarepta and as a member of Sarepta's Executive Committee, he leads f
LEXINGTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced the extension and expansion of its research collaboration with Janssen Biotech, Inc. ("Janssen"). The collaboration is designed to explore the potential for Microbiome Metabolic Therapies (MMT™) to prevent childhood-onset of atopic, immune and metabolic conditions by promoting healthy function of the gut microbiome. Since the beginning of the collaboration, Kaleido's propr
- Generate is harnessing the power of data and machine learning at scale to program biology, dramatically improve the human condition, and democratize biotherapeutics - New capital will enable the company to evolve its technology platform, rapidly scale the organization, and advance multiple programs toward IND Generate Biomedicines, whose machine learning-powered Generative Biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced it has raised $370 Million in a Series B financing to advance the development of its novel drug generation platform. The Generate platform can rapidly generate ant
KB295 reached its primary endpoint demonstrating favorable safety and tolerability profile Reduction in key ulcerative colitis biomarkers correlated with disease activity and inflammation - fecal calprotectin, fecal lactoferrin, and FimH - observed at end of study Virtual R&D Presentation, highlighting the ulcerative colitis and chronic obstructive pulmonary disease programs, to be held today at 8:00 a.m. ET LEXINGTON, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore g
Latest data and clinical development plans for KB295 in ulcerative colitis (UC) to be presented Call to feature leading experts in UC and Chronic Obstructive Pulmonary Disease (COPD) Company plans to advance both KB295 and KB109 to Phase 2 studies LEXINGTON, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that it will host a virtual R&D Presentation on October 5, 2021, at 8 a.m. ET. The agenda will feature an update on the Company's corporate strategy, data from the non-IND stu
CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for
CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h
CAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President and Head of Platform Biology. Dr. Milstein most recently served as the Vice President of platform biology at Korro Bio, Inc., and previously led the RNAi Lead Development group at Alnylam Pharmaceuticals, Inc. Dr. Milstein will be responsible for advancing Senda's platform and scaling the Company's efforts to unlock a new class of fully programmable medicines.
CAMBRIDGE, Mass., Jan. 25, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Tom DiLenge has joined the company in a newly created role as Senior Partner, Global Public Policy, Regulatory & Governmental Strategy. In this role, DiLenge will lead and develop Flagship's public policy, regulatory, and government affairs functions to advance Flagship's priorities at the federal, state, and global levels. In addition, he will serve as an in-house advisor and expert resource to Flagship's ecosystem companies. Tom brings to Flagship Pi
Estepan brings to Cellarity's BOD deep experience and expertise in all aspects of finance, corporate strategy, investor relations, and business development, and a dedication to directly improving patient lives through innovation in medicine Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointment of Ian M. Estepan to its Board of Directors. Mr. Estepan currently serves as Executive Vice President and Chief Financial Officer (CFO) of Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases. At Sarepta and as a member of Sarepta's Executive Committee, he leads f
CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Justine Levin-Allerhand, Ph.D., has joined the company in a newly created role as Senior Partner, Corporate Development. In this role, Levin-Allerhand will develop, lead, and implement best practices in Board governance, Board development, and Board member selection and recruitment across Flagship's enterprise of companies. In addition, she will advance corporate development broadly, including building new relationships with limited partners and building partnerships with aligned research and academic institutions.
LEXINGTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (NASDAQ:KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced the appointment of Alison Long, M.B.B.Ch., Ph.D., to its leadership team as Chief Medical Officer, effective December 15, 2021. In her new role, Dr. Long will be responsible for leading the development of Kaleido's ongoing and future clinical programs, including the development of KB295 and KB109 in ulcerative colitis and chronic obstructive pulmonary disease, respectively.
New Board Members Will Help Advance ‘Gene Writing' Platform and Mission to Cure Disease by Writing in the Code of Life Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the company's Board of Directors. This announcement represents the latest key development for Tessera, following the March appointments of David Davidson, M.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. as Chief Operating Officer, and Lin Guey, Ph.D. as Senior Vice President of Rare Diseases Program Strategy and Operations, and a $230 million Series B fundraising round in January. "Elliott and Mary brin
Chardan Capital reiterated coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $3.00 from $11.00 previously
Chardan Capital reiterated coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $11.00 from $15.00 previously
JMP Securities reiterated coverage of Kaleido Biosciences with a rating of Market Outperform and set a new price target of $22.00 from $25.00 previously
Morgan Stanley downgraded Kaleido Biosciences from Equal-Weight to Underweight and set a new price target of $3.00
Morgan Stanley reiterated coverage of Kaleido Biosciences with a rating of Equal Weight and set a new price target of $12.00 from $13.00 previously
Morgan Stanley reiterated coverage of Kaleido Biosciences with a rating of Equal-Weight and set a new price target of $12.00 from $13.00 previously
Canaccord Genuity resumed coverage of Kaleido Biosciences with a rating of Buy and set a new price target of $19.00
Piper Sandler initiated coverage of Kaleido Biosciences with a rating of Overweight and set a new price target of $19.00